A venture capital and private equity firm focuses on investments in the life sciences sector, with a primary emphasis on pharmaceuticals and therapeutics, and a secondary interest in medical devices. The firm invests from Series A through growth-stage transactions and is currently deploying capital from its third fund. Typical investment sizes range from $10 million to $40 million.
The firm prioritizes opportunities with a de-risked clinical development pathway, such as those involving repurposed or reformulated drugs, established mechanisms of action, 505(b)(2) regulatory strategies, or programs with proof-of-concept clinical data. For therapeutic assets, the firm primarily targets clinical-stage companies, ideally with completed Phase I trials. For medical devices, the firm considers clinical-stage opportunities with a clear regulatory and commercialization path. The firm is indication-agnostic but maintains a strong interest in 505(b)(2) products.
The firm seeks companies with a clearly defined path to regulatory approval, supported by robust intellectual property and market exclusivity. It plays an active role in its portfolio companies and takes a board seat in every investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment